Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Kahn

Seattle, WA Medical Doctor

NPI 1104901800 CMS profile 4463

1660 S Columbian Way, Ms# 151, Seattle, WA 98108

Open in the dashboard

General payments

$442,242

313 records reported · program years 2019–2025

Research payments

$99,902

Paid to them · 31 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Kahn of Seattle, WA is reported in the CMS Open Payments database as having received $442,242 across 313 general payments and $99,902 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,564 48
2025 Research $31,831 2
2024 General $88,908 61
2023 General $36,573 27
2023 Research $35,186 20
2022 General $45,399 39
2022 Research $9,100 2
2021 General $33,889 11
2021 Research $3,100 2
2020 General $32,034 12
2020 Research $10,350 4
2019 General $135,875 115
2019 Research $10,334 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Kahn
  • Washington median
  • Middle half of Washington
  • National median

In program year 2025, general payments to Steven Kahn were reported at $69,564. Among 15,799 Washington profiles paid that year, the median was $133 and the middle half received between $42 and $442.

Show as a table
Year Steven Kahn Washington median Middle half National median
2019 $135,875 $126 $38–$506 $163
2020 $32,034 $90 $30–$291 $114
2021 $33,889 $107 $29–$344 $132
2022 $45,399 $124 $38–$398 $149
2023 $36,573 $129 $40–$423 $160
2024 $88,908 $133 $44–$454 $164
2025 $69,564 $133 $42–$442 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $132,218 93 payments
  2. Eli Lilly and Company $102,918 103 payments
  3. Novo Nordisk AS $70,236 23 payments
  4. Boehringer Ingelheim b.v. $41,693 10 payments
  5. Novo Nordisk Inc $27,495 15 payments
  6. Amgen Inc. $16,442 17 payments
  7. Pfizer Inc. $13,089 8 payments
  8. Boehringer Ingelheim South Africa (Pty) Ltd $11,583 11 payments
  9. Boehringer Ingelheim MENA (Scientific Office) FZ-LLC $9,500 4 payments
  10. Boehringer Ingelheim Korea LTD. $3,700 1 payment
  11. Other $13,368 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $207,269 40 payments
  2. Travel and Lodging $151,531 157 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,376 20 payments
  4. Food and Beverage $5,002 94 payments
  5. Education $65 2 payments
Products named General payments · program years 2019–2025
  1. TRADJENTA $42,639 13 payments
  2. JARDIANCE $32,143 23 payments
  3. Korlym $1,289 13 payments
  4. MOUNJARO $491 9 payments
  5. JANUVIA $363 6 payments
  6. ZEGALOGUE $189 1 payment
  7. Ozempic $65 2 payments
  8. ATACAND $58 1 payment
  9. INVOKANA $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $48,500 19 payments
  2. Amgen Inc. $31,831 2 payments
  3. Eli Lilly and Company $18,284 2 payments
  4. Corcept Therapeutics $1,286 8 payments

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record